Close Menu

NEW YORK (GenomeWeb) – Adaptive Biotechnologies plans to collaborate with Amgen to develop and commercialize Adaptive's next-generation sequencing-based immune profiling assay, ClonoSeq, to assess minimal residual disease in patients with acute lymphoblastic leukemia, Adaptive said today.

As part of the collaboration, the companies plan to collect MRD data in order to establish validated thresholds of residual disease that can predict patient outcomes in ALL.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.